Appia Bio
ClosedLos Angeles, United States · Founded 2020 · $52.0M raised
- Headquarters
- Los Angeles, California
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- appiabio.com
- Total Funding
- $52.0M
- Last Round
- $52.0M Series AMay 2021
- Rounds
- 1
About
Develops allogeneic CAR‑iNKT cell therapies from hematopoietic stem cells to treat cancers, partnering with industry for clinical development.
Summary
Appia Bio is a Biotech company based in Los Angeles, United States, founded in 2020. It has raised $52.0M in total across 1 round, most recently a $52.0M Series A round in May 2021. Investors include 8VC and Two Sigma Ventures.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2021
Investors
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...